Scottish HTA Requests More Data For Orphan Drugs
The SMC, Scotland’s health technology appraisal body, wants more data for Albireo Pharma’s ultra-orphan Bylvay and Novartis’s rare disease drug Adakveo.
You may also be interested in...
Bylvay, the first licensed treatment for the rare liver condition PFIC, is cost effective, health technology assessment body NICE now says of the Albireo Pharma drug.
Health technology assessment body NICE has also issued guidances rejecting three products.
The scheme still includes high rebate rates, but a controversial life cycle adjustment mechanism has been dropped.